Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Adv Healthc Mater. 2018 Jun 14;7(17):e1800332. doi: 10.1002/adhm.201800332

Figure 5.

Figure 5.

Effect of ZnO NPs on the Akt/mTOR signaling pathway. (a) Western blotting analysis of the expression of mTOR/p-mTOR, Akt/p-Akt and S6/p-S6 in the U-2OS cells after they were treated with ZnO NPs for 24 h. (b) CCK-8 analysis of U-2OS cells after they were pretreated with rapamycin for 2 h and exposed to ZnO NPs (40µg/ml) for 24 h. Statistically significant differences were evaluated using the paired Dunnett`s t-test or one-way ANOVA. Results were expressed as the mean ± S.D. from three independent experiments. *P<0.05 versus control.